Product, Press Release

Hikma signed exclusive agreement for Peramvir IV for the MENA region

In line with Hikma policy to provide the people in MENA region with the newest and needed medications, on December 2009 Hikma has signed an agreement with BioCryst Pharmaceuticals Inc to exclusively represent them in this region for Peramivir IV. Peramivir (an investigational drug on phase III clinical trials) is a neuraminidase inhibitor that has been authorized by the FDA for emergency use for the treatment of certain hospitalized patients with known or suspected 2009 H1N1 influenza (swine flu).